United Therapeutics Corporation

Report azionario NasdaqGS:UTHR

Capitalizzazione di mercato: US$24.0b

United Therapeutics Performance degli utili passati

Criteri Il passato verificati 4/6

United Therapeutics ha registrato una crescita degli utili a un tasso medio annuo di 21.9%, mentre il settore Biotechs ha registrato utili in crescita a un tasso medio annuo di 33.8%. I ricavi sono stati in crescita a un tasso medio annuo di 16.2%. Il ritorno sul capitale proprio di United Therapeutics è 21.8% e ha margini netti di 40.6%.

Informazioni chiave

21.90%

Tasso di crescita degli utili

22.23%

Tasso di crescita dell'EPS

Biotechs Crescita del settore17.04%
Tasso di crescita dei ricavi16.16%
Rendimento del capitale proprio21.82%
Margine netto40.61%
Ultimo aggiornamento sugli utili31 Mar 2026

Aggiornamenti sulle prestazioni recenti

Recent updates

Aggiornamento della narrazione • May 17

UTHR: Soft Mist Inhaler Shift Will Pressure Pulmonary Hypertension Expectations

Narrative Update The updated analyst price target for United Therapeutics has edged down by $3 to $516, as analysts factor in a mix of slightly lower projected revenue growth, higher expected profit margins, and a reduced future P/E multiple, following a wave of recent target hikes and one trim across the Street. Analyst Commentary Recent research on United Therapeutics is mixed.
Aggiornamento della narrazione • Apr 28

UTHR: IPF And Pulmonary Hypertension Data Will Drive Balanced Future Expectations

Analysts lifted their fair value estimate for United Therapeutics to $519 from $471, citing updated assumptions around revenue growth, profit margins, and future P/E multiples. These updates were informed by a wave of higher Street price targets following encouraging IPF and pulmonary hypertension data and the planned soft mist treprostinil inhaler launch.
Seeking Alpha • Apr 22

United Therapeutics: The Future Lies With Manufactured Organs

Summary United Therapeutics is rated a long-term Buy, driven by its pioneering efforts in xenotransplantation and organ manufacturing. Current revenue relies heavily on treprostinil-based therapies, but future growth is expected from FDA-approved lab-grown organs by 2030. Patent expirations and competition present near-term risks, yet margins have improved and the company remains well-positioned for transition. Commercial-scale organ facilities and clinical milestones between 2028-2030 are critical catalysts for UTHR's valuation and portfolio transformation. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Apr 14

UTHR: IPF Lung Data Will Shape Future Pulmonary Franchise Outlook

Analysts have lifted the implied fair value estimate for United Therapeutics from about $592 to roughly $644, as higher Street price targets supported by more constructive views on Tyvaso, ralinepag and TreSMI, and a slightly richer assumed future P/E multiple, feed into modestly stronger revenue growth and margin assumptions. Analyst Commentary Street research around United Therapeutics has turned more constructive, with several bullish analysts revisiting their models following clinical updates on ralinepag and the TETON-1 study, along with the introduction of the TreSMI soft mist inhaler and management's longer term revenue ambitions.
Aggiornamento della narrazione • Mar 31

UTHR: Pulmonary Fibrosis Promise Will Ultimately Fall Short Of Expectations

United Therapeutics' analyst fair value estimate has shifted from $423 to $471 as analysts factor in recent TETON-1 and ralinepag data, updated profit margin assumptions, and a modestly higher future P/E. Analyst Commentary Street research around United Therapeutics has become more focused on the readthrough from TETON-1 in idiopathic pulmonary fibrosis, the Phase 3 ralinepag results in pulmonary arterial hypertension, and the planned soft mist inhaler for treprostinil.
Aggiornamento della narrazione • Mar 16

UTHR: IPF And PAH Data Plus New Inhaler Will Shape Outlook

The analyst fair value estimate for United Therapeutics has been raised from $572.00 to $592.25 as analysts factor in higher assumed revenue growth, slightly stronger profit margins, and supportive Street research that highlights upcoming idiopathic pulmonary fibrosis and pulmonary arterial hypertension catalysts, as well as the planned soft mist treprostinil inhaler. Analyst Commentary Recent Street research around United Therapeutics clusters around two big themes, the pulmonary arterial hypertension and idiopathic pulmonary fibrosis pipeline, and the shift toward next generation treprostinil delivery, including the soft mist inhaler.
Aggiornamento della narrazione • Mar 02

UTHR: Ralinepag Phase 3 Success And New Inhaler Will Drive Upside

Narrative Update: United Therapeutics (UTHR) The updated analyst price target for United Therapeutics has moved from $531.25 to $572.00. This reflects analysts' higher conviction in ralinepag following stronger than expected Phase 3 data, as well as the potential long term contribution from the planned treprostinil soft mist inhaler program.
Nuova narrazione • Feb 21

The Organ Manufacturing Frontier: More Than Just a Pharma Play?

As of February 2026, United Therapeutics has solidified its position as a dominant force in the pulmonary arterial hypertension (PAH) market. The company’s "Tyvaso" franchise has seen a 22% year-over-year surge in adoption, particularly as the DPI (Dry Powder Inhaler) version takes market share from more invasive delivery methods.
Aggiornamento della narrazione • Feb 16

UTHR: Organ Manufacturing And Sector M&A Capital Will Support Future Upside

United Therapeutics' analyst price target edges higher to $645 from $600, as analysts point to a slightly higher fair value estimate of about $531 per share and a modestly adjusted future P/E assumption around 14x, even as they flag ongoing sector level capital and M&A crosscurrents. Analyst Commentary Analysts are updating their views on United Therapeutics as they reset expectations for both the company and the broader Biotech sector heading into 2026.
Aggiornamento della narrazione • Feb 02

UTHR: Organ Manufacturing Pipeline And Sector M&A Prospects Will Drive Future Upside

Analysts have nudged their price target higher for United Therapeutics, with updated assumptions pointing to a fair value of about $530.84 per share versus roughly $518.25 previously, supported by slightly higher projected revenue growth and a modestly richer future P/E multiple. Analyst Commentary Recent commentary has focused on what United Therapeutics might look like as the Biotech sector heads into 2026 with cautious optimism.
Aggiornamento della narrazione • Jan 19

UTHR: Respiratory Franchise Execution And Xenotransplantation Progress Will Drive Future Upside

Analysts have raised their price target on United Therapeutics to US$645 from US$575, citing stronger expectations for Tyvaso and Yutrepia revenue, higher projected revenue growth and profit margins, and a lower assumed future P/E multiple, even with a slightly higher discount rate. Analyst Commentary Recent Street research on United Therapeutics has leaned positive, with several bullish analysts lifting their price targets and pointing to execution on key respiratory drugs as a central theme.
Aggiornamento della narrazione • Jan 05

UTHR: Pulmonary And IPF Pipeline Momentum Will Support Balanced Future Prospects

Analysts have lifted their blended price targets for United Therapeutics into a roughly US$525 to US$587 range, largely reflecting confidence in Tyvaso-driven Q3 revenue momentum, early Yutrepia uptake, and expectations that the broader pulmonary and IPF franchises and partnership optionality can support the company’s long-term earnings profile. Analyst Commentary Street research around United Therapeutics is clustered around higher price targets in the US$525 to US$587 range, with one firm trimming its target slightly while staying on the sidelines.
Aggiornamento della narrazione • Dec 15

UTHR: Future Pulmonary Fibrosis Upside Will Prove Overestimated

We are raising our fair value estimate for United Therapeutics to $423 per share from $320.81, as analysts lift price targets following another record Tyvaso quarter, a strong early Yutrepia launch, and growing conviction that pulmonary fibrosis and ex U.S. partnership opportunities can materially accelerate revenue growth and support higher long term margins. Analyst Commentary Street research following the latest quarter has been broadly constructive, with several firms lifting price targets on the back of record Tyvaso performance and a better than expected Yutrepia launch.
Aggiornamento della narrazione • Dec 01

UTHR: Resilient Core And Clinical Milestones Will Support Balanced Prospects Ahead

The analyst price target for United Therapeutics has increased by $5 to reflect continued strong Tyvaso performance, a robust IPF opportunity, and a resilient core business, according to analysts. Analyst Commentary Recent updates from Wall Street reflect a dynamic range of sentiment regarding United Therapeutics, with several notable price target adjustments following the latest quarterly results and clinical developments.
Aggiornamento della narrazione • Nov 17

UTHR: Record Clinical Data And Expanding Pipeline Will Support Balanced Outlook Ahead

United Therapeutics’ analyst price targets have increased, with the fair value estimate rising from $510.77 to $513.00. Analysts point to strong Tyvaso revenue growth, robust product launches, and long-term opportunities in idiopathic pulmonary fibrosis.
Aggiornamento della narrazione • Oct 31

UTHR: Recent Clinical Success Will Drive Expansion Into New Pulmonary Markets

United Therapeutics' analyst price target has increased from approximately $493 to $511, as analysts cite strong Tyvaso revenue growth, robust product launches, and positive trial data. These factors support improved profit expectations and future growth prospects.
Aggiornamento della narrazione • Oct 17

Phase III Readouts Will Broaden Pulmonary And Regenerative Markets

The analyst price target for United Therapeutics has increased modestly by approximately $8 to $492.85. Analysts cite greater confidence in the company’s future sales and profit margins following recent positive clinical trial outcomes and updated research coverage.
Aggiornamento della narrazione • Oct 03

Phase III Readouts Will Broaden Pulmonary And Regenerative Markets

United Therapeutics' analyst price target has climbed significantly, rising from approximately $467 to nearly $485 per share. Analysts cite robust Phase 3 results for Tyvaso in idiopathic pulmonary fibrosis and a strengthened outlook for future sales growth.
Aggiornamento della narrazione • Sep 18

Phase III Readouts Will Broaden Pulmonary And Regenerative Markets

Analysts raised their price target for United Therapeutics to $466.82, citing strong TETON-2 Phase 3 data for Tyvaso in IPF that de-risk future revenue, support peak sales projections, and heighten confidence in market exclusivity and regulatory approvals. Analyst Commentary Bullish analysts raised price targets significantly following strong Phase 3 TETON-2 data for Tyvaso in idiopathic pulmonary fibrosis (IPF), with the drug meeting primary and key secondary endpoints and demonstrating competitive, clinically meaningful efficacy.
Articolo di analisi • Sep 03

United Therapeutics Corporation (NASDAQ:UTHR) Surges 38% Yet Its Low P/E Is No Reason For Excitement

United Therapeutics Corporation ( NASDAQ:UTHR ) shareholders would be excited to see that the share price has had a...
Aggiornamento della narrazione • Sep 03

Phase III Readouts Will Broaden Pulmonary And Regenerative Markets

United Therapeutics’ consensus price target has been raised from $380.57 to $399.90, reflecting heightened analyst optimism following positive Phase 3 TETON-2 Tyvaso IPF results that signal a multibillion-dollar sales opportunity and improved revenue outlook despite competitive and litigation risks. Analyst Commentary Bullish analysts increased price targets sharply following "surprisingly positive" Phase 3 TETON-2 results for Tyvaso in idiopathic pulmonary fibrosis (IPF), citing clinically meaningful FVC benefit, strong statistical significance, and a competitive efficacy profile compared to pipeline peers.
Articolo di analisi • Jul 22

Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Seeking Alpha • Feb 25

United Therapeutics: A Unique Business With High Margins And Expansion Potential

Summary United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by Tyvaso (+33% YoY), and maintains high margins and low debt burden, with a 39% growth potential. Key growth drivers include Tyvaso's expansion into IPF, Ralinepag development, xenotransplantation breakthroughs, and international market expansion. Despite risks from patent expirations and legal challenges, UTHR's diversified portfolio and strong financials position it well for sustained growth. Read the full article on Seeking Alpha
Seeking Alpha • Nov 14

United Therapeutics: One To Believe In Despite Competitive Threats

Summary United Therapeutics Corporation's stock has surged over 300% since my 2020 “Buy” rating, driven by strong sales of Tyvaso DPI and other PAH treatments. Despite facing generic competition, United has maintained resilience, leveraging strategic litigation and innovative product development to protect and grow its revenue streams. United's future growth hinges on expanding Tyvaso DPI's market and advancing its pipeline, including promising IPF treatments and groundbreaking organ transplant technologies. With over $4 billion in cash and a visionary CEO, UTHR is well-positioned for continued double-digit revenue growth and potential M&A opportunities. Read the full article on Seeking Alpha
User avatar
Nuova narrazione • Aug 22

Innovative Biotech Products Pave The Way For A Future Revenue Surge And Market Leadership

Advancements in treatments for pulmonary hypertension and fibrosis, and pioneering Xenotransplantation products, promise to lead market growth and address unmet medical needs.
Seeking Alpha • Aug 20

United Therapeutics: Economics Support Compounding Ability

Summary United Therapeutics Corporation remains a buy with strong growth potential and high returns on invested capital. Q2 FY'24 earnings show continued growth in sales and earnings, with upsides in its Tyvaso segment. The company has started share buybacks and is on track to reach a $3 billion revenue run rate by FY'25, supporting a valuation of $400/share. Read the full article on Seeking Alpha

Ripartizione dei ricavi e delle spese

Come United Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storico di utili e ricavi

NasdaqGS:UTHR Ricavi, spese e utili (USD Millions )
DataRicaviUtiliSpese G+ASpese di R&S
31 Mar 263,1701,287745539
31 Dec 253,1831,335731550
30 Sep 253,1281,272706544
30 Jun 253,0781,242679520
31 Mar 252,9941,211661526
31 Dec 242,8771,195635481
30 Sep 242,7561,111607499
30 Jun 242,6171,069581480
31 Mar 242,4981,051533429
31 Dec 232,328985474408
30 Sep 232,204900499351
30 Jun 232,111872470332
31 Mar 231,981728481337
31 Dec 221,936727473323
30 Sep 221,860707448312
30 Jun 221,789631458324
31 Mar 221,768687429304
31 Dec 211,686476466410
30 Sep 211,655462499450
30 Jun 211,591471451440
31 Mar 211,506405444456
31 Dec 201,483515421358
30 Sep 201,410469364345
30 Jun 201,431430402362
31 Mar 201,443528336350
31 Dec 191,449-1043351,174
30 Sep 191,519-923131,199
30 Jun 191,530-1183241,214
31 Mar 191,601-1503671,220
31 Dec 181,628589269358
30 Sep 181,711543348333
30 Jun 181,744713285287
31 Mar 181,744484270264
31 Dec 171,725418333265
30 Sep 171,670509311218
30 Jun 171,632395363209
31 Mar 171,600657368184
31 Dec 161,599714319148
30 Sep 161,595708326157
30 Jun 161,5731,011209120
31 Mar 161,507904246135
31 Dec 151,466652453245
30 Sep 151,407663385241
30 Jun 151,351173604350

Guadagni di qualità: UTHR ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di UTHR (40.6%) UTHR sono più alti rispetto allo scorso anno (40.4%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di UTHR sono cresciuti in modo significativo del 21.9% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di UTHR nell'ultimo anno ( 6.3% ) è inferiore alla media quinquennale ( 21.9% all'anno).

Guadagni vs Settore: La crescita degli utili UTHR nell'ultimo anno ( 6.3% ) non ha superato quella del settore Biotechs 43%.

Rendimento del capitale proprio

ROE elevato: Il Return on Equity ( 21.8% ) di UTHR è considerato alto.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/22 03:46
Prezzo dell'azione a fine giornata2026/05/22 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

United Therapeutics Corporation è coperta da 34 analisti. 14 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jasper HellwegArgus Research Company
James BirchenoughBarclays
Derek TallerBenchmark Company